Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in chinese volunteers identified as CYP2C19 poor and extensive metabolizers

Annals of Pharmacotherapy

Volumn 43, Issue 4, 2009, Pages 726-731

  Lei, He Ping ^a   Wang, Guo ^a   Wang, Lian Sheng ^a   Ou Yang, Dong Sheng ^a   Chen, Hao ^b   Li, Qing ^a   Zhang, Wei ^a   Tan, Zhi Rong ^b   Fan, Lan ^a   He, Yi Jing ^b   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NONE

Author keywords

CYP2C19; Genetic polymorphism; Ginkgo biloba; Voriconazole

Indexed keywords

CYTOCHROME P450 2C19; GINKGO BILOBA EXTRACT; VORICONAZOLE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CROSS-OVER STUDIES; DRUG INTERACTIONS; ENZYME INDUCTION; GINKGO BILOBA; HUMANS; MALE; PHYTOTHERAPY; POLYMORPHISM, GENETIC; PYRIMIDINES; TRIAZOLES; YOUNG ADULT;

EID: 65849263344     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L537     Document Type: Article

References (31)

1. Cuenca-Estrella M, Rodríguez-Tudela JL, Mellado E, Martínez-Suárez JV, Monzón A. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998;42:531-533 (Pubitemid 28473016)
2. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36:198-202.
3. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006;45:649-663 (Pubitemid 43990568)
4. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415
5. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003;31:540-547 (Pubitemid 36444162)
6. CYP2C19 information. www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=124020 (accessed 2008 Oct 16).
7. Human Cytochrome P450 Allele Nomenclature Committee. CYP2C19 allele nomenclature. www.cypalleles.ki.se/cyp2C19.htm (accessed 2008 Oct 16).
8. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58:521-590
9. Kurzawski M, Gawroñska-Szklarz B, Wrzes̃niewska J, Siuda A, Starzyñska T, Droz̃dzik M. Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients. Eur J Clin Pharmacol 2006;62:877-880
10. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64.
11. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-598
12. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4¢-hydroxylase in humans. Biochemistry 1994;33:1743-1752
13. Ferguson RJ, de Morais SM, Benhamou S, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998;284:356-361 (Pubitemid 28109566)
14. Sim SC, Risinger C, Dahl M-L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006;79:103-113
15. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther 2008;83:322-327
16. Rengelshausen J, Banfield M, Riedel K-D, et al. Opposite effects of short-term and long-term St. John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005;78:25-33.
17. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004;75:587-588 (Pubitemid 38746611)
18. Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000;81:668-678
19. Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal, I. Progress Drug Res 2001;56:1-76.
20. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. Pharmacogenetics and herb- drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004;14:841-850
21. Hägg S, Spigset O, Dahlqvist R. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 2001;51:169-173 (Pubitemid 32216067)
22. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-15422
23. de Morais SM, Goldstein JA, Xie HG, et al. Genetic analysis of the Smephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-411
24. Garey KW, Peloquin CA, Godo PG, Nafziger AN, Amsden GW. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. Antimicrob Agents Chemother 1999;43:1152-1155 (Pubitemid 29214739)
25. Mikus G, Schöwel V, Drzewinska M, et al. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther 2006;80:126-135
26. Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006;46:1290-1298
27. Smith M, Lin KM, Zheng YP. An open trial of nifedipine-herb interactions with St. John's wort, ginseng, and Ginkgo biloba (abstract). Clin Pharmacol Ther 2001;69:P86.
28. Kressman S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002;54:661-669
29. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:425-432
30. Jacobs BP, Browner WS. Ginkgo biloba: a living fossil. Am J Med 2000;108:341-342
31. Christen Y, Maixent JM. What is Ginkgo biloba extract EGb 761? An overview - from molecular biology to clinical medicine. Cell Mol Biol (Noisy-le-grand) 2002;48:601-611